File size: 5,418 Bytes
98be852
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
db137bd
 
98be852
 
 
db137bd
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
98be852
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
153a479
 
98be852
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9995f5e
cfca820
 
98be852
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
bf52997
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
{
 "spec": "v1.1",
 "categories": [
  {
   "id": "A",
   "name": "ํก์ˆ˜",
   "en": "Absorption",
   "icon": "๐Ÿซ—",
   "desc": "๋จน์€ ์•ฝ์ด ๋ชธ ์•ˆ์œผ๋กœ ๋“ค์–ด์˜ค๋Š”๊ฐ€",
   "planned": 8,
   "boards": [
    "Solubility",
    "LogP",
    "Caco2"
   ],
   "desc_en": "Whether an orally dosed compound enters the body at all"
  },
  {
   "id": "D",
   "name": "๋ถ„ํฌ",
   "en": "Distribution",
   "icon": "๐Ÿฉธ",
   "desc": "ํ˜ˆ์•ก ๋‹จ๋ฐฑ์งˆ์— ๋ถ™๋Š”๊ฐ€ ยท ๋‡Œ๊นŒ์ง€ ๊ฐ€๋Š”๊ฐ€",
   "planned": 5,
   "boards": [
    "PPB",
    "Vdss"
   ],
   "desc_en": "Binding to plasma protein; passage across the blood-brain barrier"
  },
  {
   "id": "M",
   "name": "๋Œ€์‚ฌ",
   "en": "Metabolism",
   "icon": "๐Ÿ”ฅ",
   "desc": "๊ฐ„์—์„œ ์–ผ๋งˆ๋‚˜ ๋นจ๋ฆฌ ์‚ฌ๋ผ์ง€๋Š”๊ฐ€ ยท ์–ด๋–ค ํšจ์†Œ๊ฐ€ ๊ฑด๋“œ๋ฆฌ๋Š”๊ฐ€",
   "planned": 7,
   "boards": [
    "CYP3A4",
    "CYP2D6",
    "CYP2C9"
   ],
   "desc_en": "How quickly the liver clears it, and which enzymes act on it"
  },
  {
   "id": "E",
   "name": "๋ฐฐ์„ค",
   "en": "Excretion",
   "icon": "๐Ÿ’ง",
   "desc": "๋ชธ ๋ฐ–์œผ๋กœ ์–ธ์ œ ๋‚˜๊ฐ€๋Š”๊ฐ€",
   "planned": 2,
   "boards": [
    "HalfLife"
   ],
   "desc_en": "When the compound leaves the body"
  },
  {
   "id": "T",
   "name": "๋…์„ฑ",
   "en": "Toxicity",
   "icon": "โ˜ ๏ธ",
   "desc": "์‹ฌ์žฅ ยท ๊ฐ„ ยท ๋ณ€์ด์›์„ฑ. ์‹ ์•ฝ์ด ๊ฐ€์žฅ ๋งŽ์ด ์ฃฝ๋Š” ์ž๋ฆฌ",
   "planned": 7,
   "boards": [
    "hERG",
    "LD50"
   ],
   "desc_en": "Cardiac, hepatic and mutagenic liability โ€” where candidates most often fail"
  },
  {
   "id": "P",
   "name": "ํšจ๋Šฅยท์—ญ๊ฐ€",
   "en": "Potency",
   "icon": "๐ŸŽฏ",
   "desc": "ํ‘œ์ ์— ์–ผ๋งˆ๋‚˜ ์„ธ๊ฒŒ ๋ถ™๋Š”๊ฐ€",
   "planned": 4,
   "boards": [
    "AChE",
    "MAOB",
    "COX2",
    "Nav17"
   ],
   "desc_en": "How tightly a compound binds its intended target"
  },
  {
   "id": "Z",
   "name": "์—ํ”ผ์ œ๋„คํ‹ฑ",
   "en": "Epigenetics",
   "icon": "๐Ÿ“–",
   "desc": "์œ ์ „์ž๋ฅผ ๋ฐ”๊พธ์ง€ ์•Š๊ณ  ์ฝ๋Š” ๋ฐฉ์‹์„ ๋ฐ”๊พผ๋‹ค",
   "desc_en": "Changing how genes are read without changing the genes",
   "planned": 5,
   "boards": [
    "BRD4",
    "HDAC1"
   ]
  },
  {
   "id": "N",
   "name": "ํ•ต์ˆ˜์šฉ์ฒด",
   "en": "Nuclear receptors",
   "icon": "๐Ÿงฟ",
   "desc": "ํ˜ธ๋ฅด๋ชฌ ์‹ ํ˜ธ๋ฅผ ๋ฐ›์•„ ์œ ์ „์ž๋ฅผ ์ผœ๊ณ  ๋ˆ๋‹ค โ€” ์œ ๋ฐฉ์•”ยท์ „๋ฆฝ์„ ์•” ํ‘œ์ ",
   "desc_en": "Hormone-driven transcription factors โ€” breast and prostate cancer targets",
   "planned": 5,
   "boards": [
    "ERalpha",
    "AR"
   ]
  },
  {
   "id": "E2",
   "name": "ํ”„๋กœํ…Œ์•„์ œ",
   "en": "Proteases",
   "icon": "โœ‚๏ธ",
   "desc": "๋‹จ๋ฐฑ์งˆ์„ ์ž๋ฅด๋Š” ํšจ์†Œ โ€” ์•Œ์ธ ํ•˜์ด๋จธยทํ•ญ์‘๊ณ ยทํ•ญ๋ฐ”์ด๋Ÿฌ์Šค๊ฐ€ ์—ฌ๊ธฐ ๊ฑธ๋ฆฐ๋‹ค",
   "desc_en": "Protein-cleaving enzymes behind Alzheimer, anticoagulant and antiviral programmes",
   "planned": 6,
   "boards": [
    "BACE1",
    "Thrombin",
    "FactorXa"
   ]
  },
  {
   "id": "K",
   "name": "ํ‚ค๋‚˜์•„์ œยท์„ ํƒ์„ฑ",
   "en": "Kinase & Selectivity",
   "icon": "๐Ÿ”‘",
   "desc": "ํ‚ค๋‚˜์•„์ œ ์ˆ˜๋ฐฑ ๊ฐœ ์ค‘ ์–ด๋””์— ๋ถ™๊ณ  ์–ด๋””๋Š” ํ”ผํ•˜๋Š”๊ฐ€",
   "planned": 13,
   "boards": [
    "EGFR",
    "JAK2",
    "PI3Ka",
    "FLT3",
    "VEGFR2",
    "CDK2",
    "HER2",
    "ABL1",
    "BRAF",
    "KIT",
    "ALK",
    "Selectivity"
   ],
   "desc_en": "Which of several hundred kinases are engaged, and which are spared"
  },
  {
   "id": "R",
   "name": "์ˆ˜์šฉ์ฒดยทGPCR",
   "en": "Receptors & GPCR",
   "icon": "๐Ÿ“ก",
   "desc": "์„ธํฌ ํ‘œ๋ฉด ์ˆ˜์šฉ์ฒด โ€” ์Šน์ธ์•ฝ ์„ธ ๊ฐœ ์ค‘ ํ•˜๋‚˜๊ฐ€ ์—ฌ๊ธฐ๋ฅผ ๋…ธ๋ฆฐ๋‹ค",
   "desc_en": "Cell-surface receptors โ€” the target class behind roughly a third of approved drugs",
   "planned": 8,
   "boards": [
    "D2",
    "HT2A",
    "MuOpioid",
    "KappaOpioid",
    "A2A",
    "CB1"
   ]
  },
  {
   "id": "S",
   "name": "๊ตฌ์กฐ๊ธฐ๋ฐ˜ ๊ฒฐํ•ฉ",
   "en": "Structure-based",
   "icon": "๐Ÿงฌ",
   "desc": "์–ด๋–ค ์ž์„ธ๋กœ ๋ถ™๋Š”๊ฐ€ ยท ๊ทธ ์ž์„ธ๊ฐ€ ๋ฌผ๋ฆฌ์ ์œผ๋กœ ๋ง์ด ๋˜๋Š”๊ฐ€",
   "planned": 4,
   "boards": [],
   "desc_en": "The binding pose, and whether that pose is physically admissible"
  },
  {
   "id": "X",
   "name": "์„ธํฌยทํ‘œํ˜„ํ˜•",
   "en": "Cell & Phenomics",
   "icon": "๐Ÿ”ฌ",
   "desc": "์•ฝ์ด ์‹ค์ œ ์„ธํฌ์— ๋ฌด์Šจ ์ง“์„ ํ•˜๋Š”๊ฐ€",
   "planned": 5,
   "boards": [
    "Phenotype"
   ],
   "desc_en": "What a compound actually does to a living cell"
  },
  {
   "id": "I",
   "name": "ํ•ญ๊ฐ์—ผยท์ „์„ธํฌ",
   "en": "Anti-infective & whole-cell",
   "icon": "๐Ÿฆ ",
   "desc": "๊ท ๊ณผ ๊ธฐ์ƒ์ถฉ์ด ์‹ค์ œ๋กœ ์ฃฝ๋Š”๊ฐ€ โ€” ๋‹จ๋ฐฑ์งˆ์ด ์•„๋‹ˆ๋ผ ์ƒ๋ฌผ์„ ์ฝ๋Š”๋‹ค",
   "desc_en": "Whether the organism actually dies โ€” the readout is a living cell, not a protein",
   "planned": 6,
   "boards": [
    "Malaria",
    "SEpidermidis",
    "MTB",
    "SAureus"
   ]
  },
  {
   "id": "C",
   "name": "์ž„์ƒ ์ธ์‹ค๋ฆฌ์ฝ”",
   "en": "Clinical in-silico",
   "icon": "๐Ÿฅ",
   "desc": "์‚ฌ๋žŒ ๋ชธ์—์„œ์˜ ๋†๋„ ยท ์•ฝ๋ฌผ ์ถฉ๋Œ ยท ์šฉ๋Ÿ‰. ๊ฒจ๋ฃฐ ํ‘œ๊ฐ€ ์•„์ง ์—†๋Š” ์ž๋ฆฌ",
   "planned": 6,
   "boards": [
    "Withdrawal"
   ],
   "desc_en": "Human exposure, drug-drug interaction and dose โ€” endpoints with no leaderboard yet"
  },
  {
   "id": "G",
   "name": "์ƒ์„ฑยท๋ชจ๋‹ฌ๋ฆฌํ‹ฐ",
   "en": "Generation & Modality",
   "icon": "โš—๏ธ",
   "desc": "์ƒˆ๋กœ ๋งŒ๋“ค์–ด ๋‚ด๋Š” ์ชฝ ยท ์†Œ๋ถ„์ž๋ฅผ ๋„˜์–ด์„œ๋Š” ์ชฝ",
   "planned": 5,
   "boards": [],
   "desc_en": "Generating new matter, and modalities beyond small molecules"
  }
 ]
}